Table 1. Characteristics of breast cancer patients.
| Clinical-pathological | cases | AR | ||
|---|---|---|---|---|
| characteristics | ARlow | ARhigh | p valueα | |
| (% of total) | (% of total) | |||
| Age (years) | ||||
| ≤50 | 226(51.7) | 141(32.3) | 85(19.5) | 0.382 |
| >50 | 211(48.3) | 123(28.1) | 88(20.1) | |
| Menopausal status | ||||
| Pre | 224(51.3) | 129(29.5) | 95(21.7) | 0.216 |
| Post | 213(48.7) | 135(30.9) | 78(17.8) | |
| TNM stageb | ||||
| I | 133(31.4) | 74(17.5) | 59(13.9) | 0.222 |
| II | 241(56.8) | 144(34.0) | 97(22.9) | |
| III | 50(11.8) | 36(8.5) | 14(3.3) | |
| Pathologicalstageb | ||||
| I | 7(1.7) | 3(0.7) | 4(1.0) | 0.622 |
| II | 293(70.8) | 176(42.5) | 117(28.3) | |
| III | 114(27.5) | 70(16.9) | 44(10.6) | |
| Tumor size (cm) | ||||
| T1(≤2) | 202(47.1) | 115(26.8) | 87(20.3) | 0.163 |
| T2 (>2_5) | 206(48) | 129(30.1) | 77(17.9) | |
| T3 (>5) | 21(4.9) | 16(3.7) | 5(1.2) | |
| Node status | ||||
| Negative | 244(56.1) | 141(32.4) | 103(23.7) | 0.745 |
| Positive | 191(43.9) | 122(28.0) | 69(15.9) | |
| ER status | ||||
| Negative | 249(57.5) | 179(41.3) | 70(16.2) | <0.01 |
| Positive | 184(42.5) | 81(18.7) | 103(23.8) | |
| PR status | ||||
| Negative | 293(67.8) | 201(46.5) | 92(21.3) | <0.01 |
| Positive | 139(32.2) | 58(13.4) | 81(18.8) | |
| HER2 status | ||||
| Negative | 255(58.9) | 150(34.6) | 105(24.2) | 0.459 |
| Positive | 178(41.1) | 111(25.6) | 67(15.5) | |
| Anthracyclines based chemo | ||||
| negative | 90(20.6) | 50(11.5) | 40(9.2) | 0.359 |
| Positive | 346(79.4) | 213(48.8) | 133(30.5) | |
| Taxane based chemo | ||||
| negative | 388(89.0) | 238(54.6) | 150(34.4) | 0.216 |
| Positive | 48(11) | 25(5.7) | 23(5.3) | |
| Local recurrence | ||||
| Negative | 354(90.8) | 205(52.6) | 149(38.2) | 0.337 |
| Positive | 36(9.2) | 23(5.9) | 13(3.3) | |
| Distant metastasis | ||||
| Negative | 316(81.0) | 176(45.1) | 140(35.9) | 0.022 |
| Positive | 74(19) | 52(13.3) | 22(5.6) | |
Abbreviations: ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor receptor 2; AR: androgen receptor
Bold values are significant (P < 0.05).
α
Compared using Student's t test or Pearson's χ2 test.
b
Classified according to the National Comprehensive Cancer Network guidelines.